Pharmacological prevention and treatment of vascular dementia: Approaches and perspectives

@article{Baskys2012PharmacologicalPA,
  title={Pharmacological prevention and treatment of vascular dementia: Approaches and perspectives},
  author={Andrius Baskys and Jin-xiang Cheng},
  journal={Experimental Gerontology},
  year={2012},
  volume={47},
  pages={887-891}
}
Effectiveness and cost-effectiveness of the pharmacological treatment of Alzheimer's disease and vascular dementia.
  • J. Versijpt
  • Medicine
    Journal of Alzheimer's disease : JAD
  • 2014
TLDR
The present manuscript reviews several factors contributing to the costs of dementia, gives an overview of available studies claiming both the effectiveness and cost-effectiveness of current dementia treatments, and highlights strengths and weaknesses of the aforementioned studies.
Integration of genomic information in development of pharmacological vascular dementia prevention and treatment strategies.
  • A. Baskys
  • Biology, Medicine
    Journal of Alzheimer's disease : JAD
  • 2014
TLDR
Analysis of gene expression data suggests that AHDs differentially regulate VaD-associated genes, which could be used as an empirical basis for the optimal selection of A HDs in clinical trials and, ultimately, for VaD prevention and treatment.
Statins and vascular dementia: a review.
TLDR
A literature search highlighted two cross-sectional studies, two prospective cohort studies, and one retrospective cohort study that found a significant positive effect of statin treatment on VaD, depicted by the lower incidence of VaD in statin users, while the others reported non-significant associations.
Mild Cognitive Impairment and Mild Dementia: The Role of Ginkgo biloba (EGb 761®)
TLDR
This drug has shown convincing results, improving cognitive function, neuropsychiatric symptoms and consequent reduction of caregiver stress and maintenance of autonomy in patients with age-related cognitive decline, MCI and mild to moderate dementia.
Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology
TLDR
There is no clear evidence that any intervention can prevent or delay the onset of dementia, and the consensus statement focuses on medication, psychological interventions can be effective in addition to pharmacotherapy, both for cognitive and non-cognitive symptoms.
Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology
TLDR
The British Association for Psychopharmacology coordinated a meeting of experts to review and revise its previous 2011 guidelines for clinical practice with anti-dementia drugs, with the consensus statement focusing on medication.
Post-stroke cognitive impairment: epidemiology, mechanisms and management.
TLDR
The epidemiological features and the mechanisms of post-stroke cognitive impairment are described, the promising management strategies for these patients are discussed, and the treatments may benefit from the anti-dementia drugs, but also the manage measures on cerebrovascular diseases.
Cholinesterase inhibitors for rarer dementias associated with neurological conditions.
TLDR
Two trials included patients with HD; one found that cholinesterase inhibitor use in the short-term had no statistically significant impact on the cognitive portion of the Alzheimer Disease Assessment Scale (ADAS-Cog), and the other found that Cholinestersterase inhibitors use inThe medium-term improved the results of the verbal fluency test.
Effect of Obesity on Cognitive Impairment in Vascular Dementia Rat Model via BDNF-ERK-CREB Pathway
TLDR
It is suggested that obesity exacerbates cognitive impairment in vascular dementia by inhibiting the compensatory increases of BDNF-ERK-CREB pathway.
Neuropsychiatric management of young-onset dementias.
...
...

References

SHOWING 1-10 OF 40 REFERENCES
Vascular dementia: Pharmacological treatment approaches and perspectives
TLDR
The current understanding of the mechanisms of nerve cell damage due to ischemia is addressed and available clinical trial data on several commonly used compounds including memantine, donepezil, galantamine, rivastigmine, nimodipine, hydergine, nicergoline, CDP-choline, folic acid are summarized.
Vascular dementia: A review of recent evidence for prevention and treatment
  • H. Kirshner
  • Medicine, Psychology
    Current neurology and neuroscience reports
  • 2009
TLDR
Vascular dementia is a common cause of late-life cognitive decline and treatment of risk factors and the same preventive measures used to avoid heart attacks and strokes are needed.
Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review
TLDR
The evidence of a preventive treatment effect aimed at vascular risk factors on cognitive decline and dementia in later life is scarce and mostly based on secondary outcome parameters.
Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia.
TLDR
No convincing evidence from the trials identified that blood pressure lowering in late-life prevents the development of dementia or cognitive impairment in hypertensive patients with no apparent prior cerebrovascular disease is identified.
Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention.
  • G. Román
  • Medicine, Psychology
    The Medical clinics of North America
  • 2002
Systematic review of statins for the prevention of vascular dementia or dementia
TLDR
Non‐hypolipidemic effects of statins, known as pleiotropic effects, are likely to explain the effect of statin on dementia, according to a systematic review of existing studies.
Donepezil for vascular cognitive impairment.
  • R. Malouf, J. Birks
  • Medicine, Psychology
    The Cochrane database of systematic reviews
  • 2004
TLDR
The clinical efficacy and tolerability of donepezil on cognitive function, clinical global impression, activities of daily living and social functioning of people with vascular cognitive impairment was well tolerated and most of the side effects were transient and were resolved by stopping the medication.
Galantamine for vascular cognitive impairment.
  • D. Craig, J. Birks
  • Medicine, Psychology
    The Cochrane database of systematic reviews
  • 2006
TLDR
The data available at the time of review suggest some advantage over placebo in the areas of cognition and executive functioning in one trial but this was not seen in a second trial which included smaller numbers of relevant patients, and more studies are needed before firm conclusions can be drawn.
...
...